Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Palisade Bio (PALI) Receivables (2016 - 2023)

Palisade Bio has reported Receivables over the past 13 years, most recently at $300000.0 for Q1 2023.

  • Quarterly Receivables changed N/A to $300000.0 in Q1 2023 from the year-ago period, while the trailing twelve-month figure was $300000.0 through Mar 2023, changed N/A year-over-year, with the annual reading at $141250.0 for FY2022, N/A changed from the prior year.
  • Receivables was $300000.0 for Q1 2023 at Palisade Bio, up from $141250.0 in the prior quarter.
  • Over five years, Receivables peaked at $466782.0 in Q1 2019 and troughed at $21064.0 in Q4 2019.
  • The 5-year median for Receivables is $246976.0 (2020), against an average of $226845.4.
  • Year-over-year, Receivables tumbled 94.12% in 2019 and then soared 1267.26% in 2020.
  • A 5-year view of Receivables shows it stood at $21064.0 in 2019, then soared by 1267.26% to $288000.0 in 2020, then tumbled by 79.51% to $59000.0 in 2021, then skyrocketed by 139.41% to $141250.0 in 2022, then soared by 112.39% to $300000.0 in 2023.
  • Per Business Quant, the three most recent readings for PALI's Receivables are $300000.0 (Q1 2023), $141250.0 (Q4 2022), and $59000.0 (Q2 2021).